Related Experiment Video
Updated: Aug 8, 2026

Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat
Published on: February 4, 2021
Two stage EDTA anti-calcification method for bioprosthetic heart valve materials
Nehir Sucu1, Kerem Karaca, Nejat Yilmaz
1Department of Cardiovascular Surgery Mersin University, School of Medicine, Mersin, Turkey. nehirsucu@yahoo.com
Background:
The aim of this study was to investigate the effect of two-stage EDTA treatment in diminishing calcific degeneration in bovine pericardial bioprosthetic heart valve material.
Material/Methods:
Conventionally preserved pericardium specimens were divided into two groups. Group I (controls, n=18) pieces were first fixed in phosphate-buffered solution (PBS)+0.6% glutaraldehyde at +4 degrees C for 24 hours, then stored in PBS+0.2% glutaraldehyde at room temperature for 6 days. Group II (study group, n=18) pieces were treated with PBS containing 100 microg/ml ethylenediaminetetraacetic acid (EDTA) at +4 degrees C for 24 hours, then fixed in PBS+0.6% glutaraldehyde as was group I at +4 degrees C for 24 hours. After a second exposure to PBS containing 100 microg/ml EDTA at room temperature for 24 hours, they were stored in PBS+0.2% glutaraldehyde at room temperature for 4 days. Pericardial patches were inserted into the dorsal pouches of 18 juvenile male Wistar rats. After 7 weeks of implantation, all the pericardium pieces were harvested from sacrificed rats. The calcium content and biomechanical properties of the explanted tissues were evaluated and also examined histopathologically.
Results:
The difference in the calcium content of the control and study groups was statistically significant. Biomechanical and histopathologic assessment also supported these findings.
Conclusions:
Application of two-stage EDTA was found to be useful in the attenuation of calcification in bioprosthetic heart valve materials with mildly increased durability. As calcification was reduced by approximately 50%, it can be considered for use with other agents as an adjuvant treatment.

